The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
G. Scagliotti
Honoraria - AstraZeneca; Lilly; Roche
I. Vynnychenko
No relevant relationships to disclose
Y. Ichinose
No relevant relationships to disclose
K. Park
Consultant or Advisory Role - Amgen
K. Kubota
No relevant relationships to disclose
F. H. Blackhall
Consultant or Advisory Role - Amgen (U)
Research Funding - Amgen
R. Pirker
No relevant relationships to disclose
R. Galiulin
No relevant relationships to disclose
T. Ciuleanu
Honoraria - Amgen
O. Sydorenko
No relevant relationships to disclose
M. Dediu
No relevant relationships to disclose
Z. Papai-Szekely
No relevant relationships to disclose
N. Martinez Banaclocha
No relevant relationships to disclose
S. McCoy
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
B. Yao
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. J. Hei
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
D. R. Spigel
Consultant or Advisory Role - Amgen (U)